Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.
Advertisement

Related Content

Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
Karyopharm Selinexor Approval Likely Awaits BOSTON Trial, But US FDA Promises To Move Quickly
Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial
Biohaven Posts Positive Migraine Results, But Investors Are Wary
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel